Trial Profile
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Sunitinib
- Indications Cancer metastases; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms IMmotion151
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 06 Jun 2023 Results describing the development and optimization of a machine learning model for assigning individual patients to biologically driven clusters in real time to facilitate RNA-seq based biomarker trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 Feb 2022 Data from studies (CheckMate 214, Keynote 426, Javelin Renal 101, CheckMate 9ER, Immotion 151, and CLEAR ) used to perform a cost effectiveness analysis of six recently approved IO-TKI drug combinations and sunitinib presented at the 2022 Genitourinary Cancers Symposium
- 20 Jan 2022 This trial has been completed in Poland (Date of the global end of the trial : 13-Dec-2021), according to European Clinical Trials Database record.